The Silverstein Foundation and Q-State Biosciences Launch Chamishi Therapeutics

NEW YORK and CAMBRIDGE, Mass., Sept 26, 2019 (GLOBE NEWSWIRE) – The Silverstein Foundation for Parkinson’s with GBA and Q-State Biosciences today announced the formation and launch of Chamishi Therapeutics, a drug discovery and development company focused on...

The Michael J. Fox Foundation and The Silverstein Foundation for Parkinson’s with GBA Grant Nearly $3 Million to Studies into Disease’s Most Common Known Genetic Contributor

NEW YORK (February 20, 2019) – The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA announce nearly $3 million in grants to studies investigating glucocerebrosidase beta acid (GBA). Mutations in the...

Silverstein Foundation founder, Jonathan Silverstein, named to Forbes Midas List of Top 100 Venture Capitalists for the 7th consecutive year

March, 2018: The Silverstein Foundation and MJFF Announce Availability of Research Funding

The Silverstein Foundation for Parkinson’s with GBA and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) Jointly Announce Availability of $3.5 Million in Fall 2018 Research Funding to Expand Understanding of the GBA gene in Parkinson’s Disease New York...

Press Release: Prevail Therapeutics Announces $75 Million Series A Financing

Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with Parkinson’s and Other Neurodegenerative Diseases New York, NY – March 8, 2018 – Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing gene...

Press Release: March 8th Workshop on Accelerating Therapeutic Development in GBA-associated PD

The Silverstein Foundation for Parkinson’s with GBA and The Michael J. Fox Foundation for Parkinson’s Research Hold Workshop to Accelerate GBA Therapeutic Development NEW YORK – March 9, 2018 – The Silverstein Foundation for Parkinson’s with GBA and The Michael J. Fox...